Baldwin Wealth Partners LLC MA Acquires 11,609 Shares of Novo Nordisk A/S $NVO

Baldwin Wealth Partners LLC MA raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 6.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 181,125 shares of the company’s stock after purchasing an additional 11,609 shares during the quarter. Baldwin Wealth Partners LLC MA’s holdings in Novo Nordisk A/S were worth $12,501,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of NVO. Copeland Capital Management LLC grew its stake in Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock valued at $27,000 after purchasing an additional 255 shares during the period. North Capital Inc. bought a new position in Novo Nordisk A/S in the 1st quarter valued at $27,000. Stone House Investment Management LLC bought a new position in Novo Nordisk A/S in the 1st quarter valued at $30,000. Disciplina Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 162.3% during the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after acquiring an additional 297 shares during the period. Finally, Spirit of America Management Corp NY bought a new position in shares of Novo Nordisk A/S during the 1st quarter worth $35,000. Institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on NVO. Berenberg Bank upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Wednesday, September 17th. Hsbc Global Res upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 1st. Morgan Stanley downgraded Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and cut their price target for the stock from $59.00 to $47.00 in a research note on Monday, September 29th. BNP Paribas Exane upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 price target for the company in a research note on Wednesday, August 13th. Finally, Rothschild Redb upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 16th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and a consensus price target of $77.50.

Novo Nordisk A/S Stock Down 1.6%

NVO stock opened at $58.64 on Friday. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $261.83 billion, a PE ratio of 16.11, a PEG ratio of 2.70 and a beta of 0.68. Novo Nordisk A/S has a twelve month low of $45.05 and a twelve month high of $120.56. The stock has a 50-day simple moving average of $55.26 and a two-hundred day simple moving average of $63.33.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. The business had revenue of $11.69 billion during the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. On average, equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were given a dividend of $0.4119 per share. This represents a dividend yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S’s dividend payout ratio (DPR) is 22.53%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.